GSTM1 and Schnyder corneal dystrophy: Like Hb Stanleyville individuals with benign disease, it is expected that these dual antisickling compounds with several innovative features would offer a unique and promising approach to SCD treatment that is superior to existing options to combat SCD pathophysiology.